Drug intelligence / Profile preview

ampicillin + erythromycin

Development stage: Preclinical
Lead developer: GSK
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A combination of two antibiotics from different classes - ampicillin (a penicillin-type antibiotic) and erythromycin (a macrolide antibiotic). This combination provides coverage against both gram-positive and gram-negative bacteria and has been studied for treating various bacterial infections, particularly pneumonia. However, in vitro studies have shown potential antagonistic effects against certain bacteria like Listeria monocytogenes.

Other names: ampicillin and erythromycinampicillin/erythromycinantibiotic prophylaxis for PPROM

Targets

PBP (Penicillin-binding protein family)23S rRNA (23S ribosomal RNA)

Beyond the preview

Go deeper on ampicillin + erythromycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ampicillin + erythromycin.

Explore the full profile